Document is current
Any future updates will be listed below
-
Authors
Park, Hyung Bae
Kim, Ki Hyun
Kim, Ju Hwan
Kim, Sang Il https://orcid.org/0000-0002-0472-8010
Oh, Yu Mi
Kang, Miseung
Lee, Seoho
Hwang, Siwon https://orcid.org/0000-0002-7546-2491
Lee, Hyeonmin
Lee, TaeJin
Park, Seungbin
Lee, Ji Eun
Jeong, Ga Ram
Lee, Dong Hyun
Youn, Hyewon https://orcid.org/0000-0003-1006-2689
Choi, Eun Young https://orcid.org/0000-0002-2441-3374
Son, Woo Chan
Chung, Sang J. https://orcid.org/0000-0002-3501-212X
Chung, Junho https://orcid.org/0000-0003-4873-8031
Choi, Kyungho https://orcid.org/0000-0003-1635-173X
-
Funding
Funding for this research was provided by:
Korea Drug Development Fund (HN21C0764)
National Research Foundation of Korea (RS-2023-00260454, 2016M3A9D3900438)
- License Information
-
More Information
Article History
Received: 30 August 2023
Accepted: 28 October 2024
First Online: 18 November 2024
Competing interests
: K.C. and E.Y.C. are founders and shareholders of Ticaros Inc. H.B.P., J.E.L., and G.R.J. are currently employees of Ticaros. K.C., J.C., H.B.P., K.H.K., S.I.K., and G.R.J. are co-inventors on the pending patent for anti-CD40 switchable CAR T cells. The other authors declare no competing interests.
